Catechins / NRF2 Cancer Research Results

Catechins, Catechins: Click to Expand ⟱
Features:
Catechins belong to the category of flavanols, which have two isomeric forms, a positive (+) form and a negative (−) form (epicatechin). The (+)-catechins have antioxidative properties, whereas the (−)-epicatechins act as pro-oxidants inducing oxidative effects.
(−)-epicatechins Examples: EGCG, EGC, GCG GC ECTG, EC (all found in green tea, and maybe dark chocolate)

Catechins — Catechins are flavan-3-ol polyphenols, a chemically heterogeneous class that includes catechin, epicatechin, epigallocatechin, epicatechin gallate, and epigallocatechin gallate, with oncology literature dominated by green-tea catechins, especially EGCG. They are best classified as natural product polyphenols / phytochemicals rather than a single drug entity. Standard abbreviations include GTCs for green tea catechins and EGCG, EGC, ECG, and EC for major individual members. Their principal natural source is Camellia sinensis, although related flavan-3-ols also occur in cocoa and some fruits. In cancer biology, catechins are best understood as pleiotropic redox-active modulators whose apparent mechanism depends strongly on structure, dose, formulation, and tumor context; for broad “catechins” entries, mechanistic confidence is therefore highest for redox stress, glycolytic interference, and apoptosis, and lower for highly specific target claims unless tied to a defined catechin.

Primary mechanisms (ranked):

  1. Redox perturbation with ROS and mitochondrial ROS increase, causing oxidative macromolecular stress and stress-linked growth suppression
  2. Glycolytic suppression, including LDHA inhibition and reduced lactate production in at least some resistant tumor models
  3. Mitochondria-linked apoptotic signaling with caspase activation after sufficient intracellular stress
  4. DNA damage amplification secondary to pro-oxidant chemistry in susceptible cancer settings
  5. Growth-factor and survival signaling attenuation for some gallated catechins, including HGF/MET and downstream AKT/ERK inhibition
  6. Transcriptional and epigenetic modulation, especially with EGCG-rich mixtures, but usually as a secondary rather than defining mechanism for “catechins” as a class

Bioavailability / PK relevance: Oral catechin exposure is limited by instability, intestinal efflux, phase II metabolism, microbial catabolism, and substantial formulation dependence. Peak plasma levels generally occur about 1–3 hours after oral dosing, but systemic concentrations are often only submicromolar to low micromolar, with gallated catechins showing particularly constrained bioavailability. This makes delivery and formulation major translation constraints for internal cancers.

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use concentrations above commonly achievable circulating levels after standard oral intake, especially for EGCG-rich extracts and other gallated catechins. Some local luminal effects, tissue accumulation, metabolite activity, or combination effects may still matter biologically, but concentration-driven cell culture findings often overstate likely systemic monotherapy potency in humans.

Clinical evidence status: Strong preclinical literature; small human and phase I-II oncology studies exist mainly for chemoprevention, biomarker modulation, or supportive care, with the most developed signal in prostate cancer prevention settings. There is no approved systemic oncology indication. The only clear regulatory deployment is topical sinecatechins for external genital/perianal warts, which should not be conflated with anticancer approval.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Redox stress and mitochondrial ROS ROS ↑; mtROS ↑; H2O2 ↑ (context-dependent) ↔ or ROS ↓ at lower / nutritional exposure; injury risk ↑ at high-dose extract exposure P-R Stress overload and growth suppression For broad catechins, the most reproducible cancer-selective mechanism is redox perturbation. This is highly structure-, dose-, and metal-context dependent, and can flip from antioxidant to pro-oxidant behavior.
2 Glycolysis and LDHA LDHA ↓; lactate production ↓ ↔ R-G Anti-glycolytic pressure and resensitization potential Direct support exists for catechin suppressing LDHA/lactate output in 5-FU-resistant gastric cancer cells; this is one of the cleaner mechanism-to-phenotype links for the generic catechin entry.
3 Mitochondria and caspase apoptosis proApCas ↑ ↔ or protective at lower exposure R-G Intrinsic apoptosis Usually downstream of redox or metabolic stress rather than a fully independent initiating event.
4 Oxidative DNA damage DNAdam ↑ ↔ or possible damage at high concentration only R-G Replication stress and loss of viability Mechanistically consistent with ROS-generating catechin chemistry; likely relevant mainly in susceptible, copper-rich, or otherwise redox-primed tumor settings.
5 HGF MET survival signaling MET phosphorylation ↓; AKT/ERK ↓ ↔ R-G Reduced migratory and survival signaling Best supported for specific gallated catechins such as EGCG and ECG rather than for all catechins equally; included as a class-relevant but not class-defining axis.
6 Transcription and epigenetic modulation tumor cell viability ↓; survival transcription programs ↓ (context-dependent) ↔ G Slower proliferation and adaptive restraint Broad catechin literature often attributes DNMT, NF-κB, AP-1, and related effects, but these data are dominated by EGCG-rich systems and are less secure for the undifferentiated “catechins” category.
7 Clinical Translation Constraint Oral exposure often below many in-vitro effect levels; extract hepatotoxicity risk; interaction complexity Liver injury risk is the main normal-tissue concern with concentrated extracts G Limits systemic monotherapy translation Main constraints are low/variable oral bioavailability, dependence on formulation and fed state, uncertain equivalence among catechin mixtures, and clinically relevant safety/interaction questions for concentrated extracts.

TSF: P: 0–30 min
R: 30 min–3 hr
G: >3 hr

Rank Catechin Abbreviation Relative effectiveness Evidence weight Main mechanisms Bioavailability Cancer selectivity Key limitations Notes
1 Epigallocatechin gallate EGCG Highest overall Strongest ROS modulation, apoptosis, cell-cycle arrest, anti-angiogenic and anti-survival signaling, epigenetic effects Low to moderate oral bioavailability Moderate Poor PK, instability, conjugation, liver risk at high-dose extracts Best-supported lead catechin overall; usually ranked first across reviews, though not always the most potent in every individual cell-line comparison.
2 Epicatechin gallate ECG Very high Moderate to strong Antiproliferative activity, apoptosis, membrane and signaling disruption, redox stress Low oral bioavailability Moderate Less studied than EGCG; PK limitations similar to other gallates Often second overall; in some comparative oral-cancer datasets ECG is among the most cytotoxic and can rival or exceed EGCG.
3 Catechin gallate CG Very high to high Moderate Antiproliferative activity, apoptosis, redox perturbation Low oral bioavailability Unclear to moderate Small evidence base; relatively sparse in vivo and translational data Usually ranked close to ECG in direct comparative cell studies; broader evidence base is much thinner than EGCG.
4 Epigallocatechin EGC Moderate Moderate ROS effects, growth inhibition, apoptosis Low to moderate oral bioavailability Unclear to moderate Generally weaker than gallated catechins Usually placed below EGCG, ECG, and CG in comparative potency rankings.
5 Gallocatechin gallate GCG Moderate Limited Likely similar to other gallated catechins: redox modulation, growth inhibition Likely low oral bioavailability Unclear Sparse comparative oncology literature Could rank higher structurally, but it stays lower here because comparative anticancer evidence is limited.
6 Epicatechin EC Low to moderate Moderate Milder redox and signaling effects; weaker direct cytotoxicity Better than EGCG for absorption in some PK settings, but still metabolized extensively Often favorable tolerability Usually weak direct anticancer potency Biologically active, but typically not a lead anticancer catechin when ranked by direct tumor-cell inhibition.
7 Catechin C Low Moderate Mild antioxidant and signaling effects; limited direct antiproliferative activity Moderate relative to gallated catechins, but still metabolized Likely favorable Weak potency in most comparative cancer-cell studies Usually grouped among the least cytotoxic tea catechins in direct comparisons.
8 Gallocatechin GC Low to unclear Limited Presumed redox and signaling effects Unclear Unclear Very sparse comparative anticancer data Placed last mainly because the evidence base is weak, not because inactivity is established.


NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
5928- Catechins,    Bioavailability of Tea Catechins and Its Improvement
- Review, Nor, NA
*BioAv↝, *BioAv↓, *ROS⇅, *NRF2↑, *BioAv↑, *Half-Life↓, *BioAv↑, *BioAv↑, BioAv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Drug Metabolism & Resistance ⓘ

BioAv↑, 1,  
Total Targets: 1

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

NRF2↑, 1,   ROS⇅, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 3,   BioAv↝, 1,   Half-Life↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:228  Target#:226  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page